TY - JOUR
T1 - Two-stage hepatectomy for colorectal cancer hepatic metastases
AU - Cunningham, Steven C.
AU - Choti, Michael A.
AU - Pawlik, Timothy M.
N1 - Funding Information:
No potential conflicts of interest relevant to this article were reported. Dr. Pawlik is supported by Grant 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH.
PY - 2008/4
Y1 - 2008/4
N2 - Colorectal cancer is the third most common cancer in the United States. Roughly one half of patients with primary colorectal cancer will develop liver metastases. When feasible, the combination of hepatic resection and chemotherapy can achieve 5-year survival rates in the range of 50% to 58%. Patients with extensive bilateral hepatic disease are often deemed not to be operative candidates because complete curative resection may not be possible while maintaining an adequate future liver remnant. More recently, a two-stage approach has been advocated as a means to achieve complete surgical extirpation of all metastatic disease. The two-stage approach usually involves an initial partial resection followed by some time to allow interval hepatic hypertrophy. Often portal vein ligation or embolization is used to augment hepatic hypertrophy. At the second operation, complete removal of all remaining hepatic metastases is achieved. In well-selected patients, two-stage hepatectomy is feasible, safe, and efficacious, with reported 3-year survival rates ranging from 35% to 86% in patients with metastases that otherwise would have been considered unresectable.
AB - Colorectal cancer is the third most common cancer in the United States. Roughly one half of patients with primary colorectal cancer will develop liver metastases. When feasible, the combination of hepatic resection and chemotherapy can achieve 5-year survival rates in the range of 50% to 58%. Patients with extensive bilateral hepatic disease are often deemed not to be operative candidates because complete curative resection may not be possible while maintaining an adequate future liver remnant. More recently, a two-stage approach has been advocated as a means to achieve complete surgical extirpation of all metastatic disease. The two-stage approach usually involves an initial partial resection followed by some time to allow interval hepatic hypertrophy. Often portal vein ligation or embolization is used to augment hepatic hypertrophy. At the second operation, complete removal of all remaining hepatic metastases is achieved. In well-selected patients, two-stage hepatectomy is feasible, safe, and efficacious, with reported 3-year survival rates ranging from 35% to 86% in patients with metastases that otherwise would have been considered unresectable.
UR - http://www.scopus.com/inward/record.url?scp=77953567142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953567142&partnerID=8YFLogxK
U2 - 10.1007/s11888-008-0016-z
DO - 10.1007/s11888-008-0016-z
M3 - Article
AN - SCOPUS:77953567142
SN - 1556-3790
VL - 4
SP - 93
EP - 99
JO - Current Colorectal Cancer Reports
JF - Current Colorectal Cancer Reports
IS - 2
ER -